Prof. Dr. Erich Schlick has joined the board of directors of NBE-Therapeutics in July 2020 as independent chairman. He studied medicine in Berlin, Mainz, Heidelberg, where he obtained a doctoral degree in Pharmacology. Subsequently he trained at the US National Cancer Institute, specializing in oncology and immunology. He holds a professorship of immune pharmacology at the University of Heidelberg. Erich Schlick is a General Partner and Managing Director at Wellington Partners, a Munich-based venture capital firm, with more than € 400 million raised dedicated to life sciences. He joined Wellington as a Partner for Life Sciences in October 2005 and has since then been responsible for a number of successful European biotech and medtech companies including Immatics and Symetis. Before this, he served as Director and Head of 3i Healthcare Germany and as Deputy Sector Head of 3i Healthcare Worldwide. Prior to venture capital, Prof. Dr. Schlick spent 15 years with BASF Pharma / Knoll AG, 10 years thereof as an executive board member with worldwide responsibility for preclinical and clinical R&D. During this time, he obtained worldwide registrations for several products in cardiovascular, metabolic and pain indications. In 1993, he established the partnership with Cambridge Antibody Technology (CAT), which led to the successful development of the blockbuster product Humira, the first fully human therapeutic monoclonal antibody for treatment of rheumatoid arthritis and other autoimmune diseases.